We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sagimet

News List

Sagimet Biosciences Receives Fast Track Designation from FDA for NASH Treatment americanpharmaceuticalreview
March 24, 2021
Sagimet Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to TVB-2640 for the treatment of patients with NASH.
FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH prnasia
March 09, 2021
Gannex Pharma Co., Ltd., a wholly-owned company of Ascletis Pharma Inc., and Sagimet Biosciences Inc. jointly announced today positive topline results from the China cohort of a Phase 2 randomized, placebo-controlled clinical trial of oral ...